製品番号: HY-104077

Remdesivir

(別名: GS-5734)

226 Cited Publications

カスタマーレビュー

Based on 226 publication(s) in Google Scholar

Remdesivir (GS-5734) is a nucleoside analogue with effective antiviral activity. Remdesivir can inhibit the synthesis of viral DNA or RNA. Remdesivir can be used for the research of infection, such as SARS-CoV and MHV infection.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.95%
CAS 番号: 1809249-37-3
分子式: C₂₇H₃₅N₆O₈P
分子量:602.58

保管条件:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Remdesivir 構造式

CAS 番号: 1809249-37-3

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (226)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

EC₅₀: 30 nM (murine hepatitis virus, delayed brain tumor cell), 74 nM (SARS-CoV, HAE cell), 74 nM (MERS-CoV, HAE cell)^[1]
EC₅₀: 3.3 μM (SARS-CoV-2), 4.7 μM (SARS-CoV-2 alpha), 32 μM (SARS-CoV-2 beta), 3.7 μM (SARS-CoV-2 gamma) and 9.2 μM (SARS-CoV-2 delta)^[3]

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
16HBE14o-	CC₅₀	41 μM Compound: Remdesivir	Cytotoxicity against human 16HBE14o- after 72 hrs by MTT assay Cytotoxicity against human 16HBE14o- after 72 hrs by MTT assay	[PMID: 34408808]
A549	CC₅₀	43 μM Compound: Remdesivir	Cytotoxicity against human A549 cells overexpressing ACE2 and TMPRSS2 incubated for 48 hrs by MTS assay Cytotoxicity against human A549 cells overexpressing ACE2 and TMPRSS2 incubated for 48 hrs by MTS assay	[PMID: 36097498]
Caco-2	CC₅₀	80 μM Compound: Remdesivir	Cytotoxicity against human Caco2 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay Cytotoxicity against human Caco2 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay	[PMID: 34273661]
Caco-2	CC₅₀	>100 μM Compound: Remdesivir	Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability	[PMID: 38432056]
Caco-2	CC₅₀	2584.38 μM Compound: REMDESIVIR	Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay	10.21203/rs.3.rs-23951/v1
Caco-2	IC₅₀	0.76 μM Compound: REMDESIVIR	Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging	10.21203/rs.3.rs-23951/v1
Calu-3	CC₅₀	97 μM Compound: Remdesivir	Cytotoxicity against human Calu-3 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay Cytotoxicity against human Calu-3 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay	[PMID: 34273661]
Calu-3	CC₅₀	>50 μM Compound: RDV	Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability after 48 hrs by Cell-Tox green based fluorescence assay Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability after 48 hrs by Cell-Tox green based fluorescence assay	[PMID: 34583312]
Calu-3	CC₅₀	>5 μM Compound: Remdesivir	Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability	[PMID: 35290044]
Calu-3	CC₅₀	>100 μM Compound: Remdesivir	Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
Calu-3	CC₅₀	>0.1 μM Compound: 1	Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability	[PMID: 36651644]
Calu-3	CC₅₀	>10 μM Compound: Remdesivir	Cytotoxicity against human Calu-3 cells infected with SARS CoV-2 USA-WA1/2020 clinical isolate assessed as reduction in cell viability incubated for 48 hrs by imaging analysis Cytotoxicity against human Calu-3 cells infected with SARS CoV-2 USA-WA1/2020 clinical isolate assessed as reduction in cell viability incubated for 48 hrs by imaging analysis	[PMID: 37482021]
Calu-3	CC₅₀	>100 μM Compound: Remdesivir	Cytotoxicity against human Calu-3 cells measured after 2 days by MTT assay Cytotoxicity against human Calu-3 cells measured after 2 days by MTT assay	[PMID: 37633203]
Calu-3	CC₅₀	>100 μM Compound: Remdesivir	Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability	[PMID: 38432056]
CCRF-CEM	CC₅₀	11.2 μM Compound: Remdesivir	Cytotoxicity against human CEM cells assessed as reduction in cell viability Cytotoxicity against human CEM cells assessed as reduction in cell viability	[PMID: 38432056]
HCT-8	CC₅₀	53.18 μM Compound: Remdesivir	Cytotoxicity against human HCT-8 cells assessed as redcution in cell viability incubated for 96 hrs by PrestoBlue reagent based assay Cytotoxicity against human HCT-8 cells assessed as redcution in cell viability incubated for 96 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
HEK-293T	CC₅₀	>100 μM Compound: Remdesivir	Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay	[PMID: 34147744]
HEL 299	CC₅₀	>10 μM Compound: Remdesivir	Cytotoxicity against human HEL 299 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Cytotoxicity against human HEL 299 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
HeLa	CC₅₀	>20 μM Compound: 3; GS-5734	Cytotoxicity against human HeLa after 4 to 5 days by Cell-Titer Glo viability assay Cytotoxicity against human HeLa after 4 to 5 days by Cell-Titer Glo viability assay	[PMID: 28792763]
HeLa	EC₅₀	0.14 μM Compound: 3; GS-5734	Antiviral activity against Ebolavirus infected in human HeLa cells after 48 hrs by immuno-staining assay Antiviral activity against Ebolavirus infected in human HeLa cells after 48 hrs by immuno-staining assay	[PMID: 28792763]
HEp-2	IC₅₀	0.11 μM Compound: 1; GS-5734	Drug metabolism in human HEp-2 cells assessed as 1-NTP metabolite concentration at EC50 over 48 hrs by LC-MS/MS analysis Drug metabolism in human HEp-2 cells assessed as 1-NTP metabolite concentration at EC50 over 48 hrs by LC-MS/MS analysis	[PMID: 33835812]
Hepatocyte	CC₅₀	2.5 μM Compound: 1; RDV	Cytotoxicity against human primary hepatocytes assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human primary hepatocytes assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
HepG2	CC₅₀	52.62 μM Compound: Remdesivir	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
HepG2	CC₅₀	11.1 μM Compound: 1; RDV	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
Huh-7	CC₅₀	>20 μM Compound: 3; GS-5734	Cytotoxicity against human HuH7 after 4 to 5 days by Cell-Titer Glo viability assay Cytotoxicity against human HuH7 after 4 to 5 days by Cell-Titer Glo viability assay	[PMID: 28792763]
Huh-7	CC₅₀	>10 μM Compound: GS-5734; 8b	Cytotoxicity against human Huh-7 cells by celltiter-glo Assay Cytotoxicity against human Huh-7 cells by celltiter-glo Assay	[PMID: 32563812]
Huh-7	CC₅₀	>10 μM Compound: RDV; GS-5734	Cytotoxicity against human Huh-7 cells by CellTiter-Glo assay Cytotoxicity against human Huh-7 cells by CellTiter-Glo assay	[PMID: 32845145]
Huh-7	CC₅₀	>10 μM Compound: RDV; GS-5734	Cytotoxicity against human Huh7 cells incubated for 6 days by cellTiter-Glo assay Cytotoxicity against human Huh7 cells incubated for 6 days by cellTiter-Glo assay	[PMID: 32845145]
Huh-7	CC₅₀	10.37 μM Compound: Remdesivir	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-glo luminescent cell viability assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-glo luminescent cell viability assay	[PMID: 34242027]
Huh-7	CC₅₀	77 μM Compound: Remdesivir	Cytotoxicity against human Huh-7 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay Cytotoxicity against human Huh-7 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay	[PMID: 34273661]
Huh-7	CC₅₀	>50 μM Compound: RDV	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 24 hrs by CellTiter-Glo analysis Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 24 hrs by CellTiter-Glo analysis	[PMID: 34583312]
Huh-7	CC₅₀	>10 μM Compound: Remdesivir	Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
Huh-7	CC₅₀	1.4 μM Compound: Remdesivir	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability	[PMID: 38432056]
Huh-7	CC₅₀	90 μM Compound: Remdesivir	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 39028935]
Macrophage	CC₅₀	>20 μM Compound: 3; GS-5734	Cytotoxicity against human primary macrophages after 4 to 5 days by Cell-Titer Glo viability assay Cytotoxicity against human primary macrophages after 4 to 5 days by Cell-Titer Glo viability assay	[PMID: 28792763]
MRC5	CC₅₀	>100 μM Compound: Remdesivir	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-glo luminescent cell viability assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-glo luminescent cell viability assay	[PMID: 34242027]
MRC5	CC₅₀	>100 μM Compound: Remdesivir	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
MT4	CC₅₀	1.7 μM Compound: 1; RDV	Cytotoxicity against human MT4 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human MT4 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
PBMC	CC₅₀	>20 μM Compound: 1; RDV	Cytotoxicity against quiescent human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against quiescent human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
PBMC	CC₅₀	14.8 μM Compound: 1; RDV	Cytotoxicity against stimulated human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against stimulated human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
PBMC	CC₅₀	2 μM Compound: Remdesivir	Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation incubated for 2 to 4 days by CellTiter 96 non-radioactive cell proliferation assay Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation incubated for 2 to 4 days by CellTiter 96 non-radioactive cell proliferation assay	[PMID: 38242544]
PBMC	CC₅₀	4.9 μM Compound: Remdesivir	Cytotoxicity against human PBMC cells assessed as reduction in cell viability Cytotoxicity against human PBMC cells assessed as reduction in cell viability	[PMID: 38432056]
PC-3	CC₅₀	1.4 μM Compound: 1; RDV	Cytotoxicity against human PC-3 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human PC-3 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
Vero	CC₅₀	>25 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells infected with SARS-CoV-2 betaCoV/KOR/KCDC03/2020 assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay Cytotoxicity against African green monkey Vero cells infected with SARS-CoV-2 betaCoV/KOR/KCDC03/2020 assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay	[PMID: 33160024]
Vero	CC₅₀	>40 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis	[PMID: 33479570]
Vero	CC₅₀	>40 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by coulter counter method Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by coulter counter method	[PMID: 34571172]
Vero	EC₅₀	0.61 μM Compound: Remdesivir	Antiviral activity against Severe acute respiratory syndrome coronavirus 2 UC-1075 infected in African green monkey Vero cells assessed as reduction in plaque formation measured after 5 days by microscopic analysis Antiviral activity against Severe acute respiratory syndrome coronavirus 2 UC-1075 infected in African green monkey Vero cells assessed as reduction in plaque formation measured after 5 days by microscopic analysis	[PMID: 34571172]
Vero	CC₅₀	70.6 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by Coulter counter analysis Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by Coulter counter analysis	[PMID: 36332548]
Vero	CC₅₀	>100 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
Vero	CC₅₀	>100 μM Compound: RDV	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36764470]
Vero	CC₅₀	>25 μM Compound: Remdesivir	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 36870624]
Vero	CC₅₀	>10 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells incubated for 5 days by neutral red uptake assay Cytotoxicity against African green monkey Vero cells incubated for 5 days by neutral red uptake assay	[PMID: 37482021]
Vero	CC₅₀	>40 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter method Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter method	[PMID: 38232463]
Vero	CC₅₀	>100 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation incubated for 2 to 4 days by CellTiter 96 non-radioactive cell proliferation assay Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation incubated for 2 to 4 days by CellTiter 96 non-radioactive cell proliferation assay	[PMID: 38242544]
Vero	EC₅₀	2.3 μM Compound: Remdesivir	Antiviral activity against SARS-CoV-2 USA-WA1/2020 infected in african green monkey Vero cells assessed as reduction in viral replication by qRT-PCR analysis Antiviral activity against SARS-CoV-2 USA-WA1/2020 infected in african green monkey Vero cells assessed as reduction in viral replication by qRT-PCR analysis	[PMID: 38242544]
Vero	CC₅₀	>100 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability	[PMID: 38432056]
Vero	CC₅₀	>25 μM Compound: Remdesivir	Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr	10.1101/2020.03.20.999730
Vero	IC₅₀	11.41 μM Compound: Remdesivir	Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr	10.1101/2020.03.20.999730
Vero C1008	EC₅₀	0.62 μM Compound: Remdesivir	Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs	[PMID: 32511357]
Vero C1008	CC₅₀	>100 μM Compound: GS-5734; 8b	Cytotoxicity against African green monkey Vero E6 cells Cytotoxicity against African green monkey Vero E6 cells	[PMID: 32563812]
Vero C1008	CC₅₀	100 μM Compound: RDV; GS-5734	Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay	[PMID: 32845145]
Vero C1008	EC₅₀	0.069 μM Compound: 52	Antiviral activity against SARS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay Antiviral activity against SARS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay	[PMID: 33486200]
Vero C1008	EC₅₀	0.074 μM Compound: 52	Antiviral activity against MERS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay Antiviral activity against MERS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay	[PMID: 33486200]
Vero C1008	EC₅₀	0.77 μM Compound: 52	Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay	[PMID: 33486200]
Vero C1008	EC₅₀	3.01 μM Compound: Remdesivir	Antiviral activity against SARS coronavirus 2 infected in Vero E6 cells assessed as plague reduction measured after 1 hr Antiviral activity against SARS coronavirus 2 infected in Vero E6 cells assessed as plague reduction measured after 1 hr	[PMID: 33639344]
Vero C1008	CC₅₀	166 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero E6 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay Cytotoxicity against African green monkey Vero E6 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay	[PMID: 34273661]
Vero C1008	CC₅₀	72 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero E6 cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells after 72 hrs by MTT assay	[PMID: 34408808]
Vero C1008	CC₅₀	373 μM Compound: RMV	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay	[PMID: 34534839]
Vero C1008	CC₅₀	>200 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 34749200]
Vero C1008	CC₅₀	>10 μM Compound: GS-5734	Cytotoxicity against african green monkey Vero E6 cells by MTS assay Cytotoxicity against african green monkey Vero E6 cells by MTS assay	[PMID: 36455356]
Vero C1008	CC₅₀	>100 μM Compound: Remdesivir	Cytotoxicity against african green monkey Vero E6 cells assessed as reduction in cell viability after 26 hrs by MTS assay Cytotoxicity against african green monkey Vero E6 cells assessed as reduction in cell viability after 26 hrs by MTS assay	[PMID: 36475694]
Vero C1008	CC₅₀	>100 μM Compound: Remdesivir	Cytotoxicity against african green monkey Vero E6 cells assessed as inhibition of cell growth by CCK-8 assay Cytotoxicity against african green monkey Vero E6 cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 36965227]
Vero C1008	EC₅₀	770 nM Compound: GS-5734	Antiviral activity against SARS-COV-2 infected in African green monkey Vero E6 cells Antiviral activity against SARS-COV-2 infected in African green monkey Vero E6 cells	[PMID: 37229831]
Vero C1008	CC₅₀	608.3 μM Compound: Cpd III	Cytotoxicity against African green monkey Vero E6 cells measured after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells measured after 72 hrs by MTT assay	[PMID: 37252103]
Vero C1008	CC₅₀	168 nM Compound: Remdesivir	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 72 hrs by crystal violet staining based analysis Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 72 hrs by crystal violet staining based analysis	[PMID: 39004019]
Vero C1008	CC₅₀	>100 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 39028935]
Vero C1008	EC₅₀	1.65 μM Compound: Remdesivir	Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days	10.1101/2020.04.03.023846
Vero C1008	EC₅₀	0.62 μM Compound: Remdesivir	Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs	10.1101/2020.04.16.044016

体外実験

Remdesivir inhibits MHV replication with an IC₅₀ of 1.1 μM in infected delayed brain tumor (DBT) cells with MHV^[1].
Remdesivir (2 μM, 2 h preinfection and 2 h postinfection) shows maximal inhibition in infected cells with MHV^[1].
Remdesivir (1-10 μM, 24-72 h) decreases SARS-CoV and MERS-CoV viral titer in HAE cells^[1].
Remdesivir inhibits 2019-nCoV with an EC₅₀ of 0.77 μM and CC₅₀ >100 μM^[2].
Remdesivir shows antiviral activity with EC₅₀ values of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Remdesivir (0.01-100 μM) reduces lung viral titers in mice models of WT and F480L + V557L SARS-CoV^[1].
Remdesivir (10 mg/kg, i.v.) shows 100% protection against Ebola virus infection in nonhuman primate (NHP) models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 1809249-37-3
性状 Solid
分子量 602.58
分子式 C₂₇H₃₅N₆O₈P
Color Off-white to yellow
SMILES

C[C@H](N[P@@](OC1=CC=CC=C1)(OC[C@H]2O[C@@](C#N)(C3=CC=C4C(N)=NC=NN43)[C@H](O)[C@@H]2O)=O)C(OCC(CC)CC)=O
別名

GS-5734
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (226)

All Bio/Physico-chemical AssayCell Proliferation/Viability AssayIF

Sort by:

Journal Impact Factor

N Engl J Med

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. [Abstract]

2023 Jan 5;388(1):89-91. PMID: 36476720
Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Signal Transduct Target Ther

Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. [Abstract]

2021 Feb 4;6(1):51. PMID: 33542181
Signal Transduct Target Ther

An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. [Abstract]

2021 Apr 24;6(1):165. PMID: 33895786
Nature

Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. [Abstract]

2021 May;593(7859):418-423 PMID: 33727703
Nature

Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. [Abstract]

2020 Jun;582(7813):561-565. PMID: 32365353

Remdesivir purchased from MedChemExpress. Usage Cited in: Nature. 2020 Jun;582(7813):561-565. [Abstract]

Remdesivir treatment showing the use of synSARS-CoV-2-GFP. Vero E6 cells were infected with synSARS-CoV-2-GFP (MOI = 0.01) and treated with 0.2 μM, 2 μM or without Remdesivir. DMSO was used as treatment in cells that were not incubated with Remdesivir. Mock, uninfected cells. At 48 h after infection, cells were analysed by fluorescence microscopy to detect GFP expression (left) and cell-culture supernatants were collected and titrated by TCID50 assay (right).
Science

Replication and single-cycle delivery of SARS-CoV-2 replicons. [Abstract]

2021 Nov 26;374(6571):1099-1106. PMID: 34648371

Remdesivir purchased from MedChemExpress. Usage Cited in: Science. 2021 Nov 26;374(6571):1099-1106. [Abstract]

Time course measurements of cell viability of Huh-7.5 cells electroporated with WT or Nsp1 K164A/H165A double mutant (Nsp1mut) Gluc replicon RNA. Cells were seeded with 100 nM Remdesivir or vehicle and were washed in phosphate-buffered saline 24 hours before each respective time-point collection. Mock-electroporated cells were used as controls for post-electroporation cell viability. The dashed line indicates the limit of detection. N = 4. Error bars indicate SD.
Science

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. [Abstract]

2020 Jun 26;368(6498):1499-1504. PMID: 32358203
Cell Res

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. [Abstract]

2020 Mar;30(3):269-271. PMID: 32020029

Remdesivir purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Mar;30(3):269-271. [Abstract]

Remdesivir (0.21-5.56 μM) inhibits virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2.
Sci Bull

Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2. [Abstract]

2021 May 15;66(9):925-936. PMID: 33318880

Remdesivir purchased from MedChemExpress. Usage Cited in: Sci Bull. 2021 May 15;66(9):925-936. [Abstract]

Immunofluorescence of intracellular viral N protein. Intracellular expression of N protein was assessed by staining of infected Vero E6 cells with the polyclonal anti-N antibody (1:1000 dilution, green). Nuclei were stained with DAPI. CPE was shown in bright field. The results showed that Remdesivir (6.25 µmol/L) significantly inhibited N protein expression.
Nat Microbiol

Brain exposure to SARS-CoV-2 virions perturbs synaptic homeostasis. [Abstract]

2024 May;9(5):1189-1206. PMID: 38548923
Nat Cell Biol

A placental model of SARS-CoV-2 infection reveals ACE2-dependent susceptibility and differentiation impairment in syncytiotrophoblasts. [Abstract]

2023 Aug;25(8):1223-1234. PMID: 37443288

Remdesivir purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2023 Aug;25(8):1223-1234. [Abstract]

Virus titre expressed in ‘Luminescence relative light units (RLU)’ and genome copy analysis of d5 infected STs ± antiviral drug treatment (Rem = Remdesivir (1 μM; 3 h); NHC = Molnupiravir).
Nat Commun

A mouse-adapted Yezo virus model for antiviral testing in immunocompetent mice. [Abstract]

2026 Mar 17;17(1):4058. PMID: 41844638
Nat Commun

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. [Abstract]

2023 Jul 15;14(1):4231. PMID: 37454219
Nat Commun

In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir. [Abstract]

2023 Jul 4;14(1):3952. PMID: 37402789
Nat Commun

Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. [Abstract]

2021 Nov 5;12(1):6415. PMID: 34741049
Nat Commun

Programmable nano-reactors for stochastic sensing. [Abstract]

2021 Oct 4;12(1):5811. PMID: 34608151
Nat Commun

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics. [Abstract]

2021 Aug 9;12(1):4887. PMID: 34373446
Acta Pharm Sin B

Insights into SARS-CoV-2 replication control via targeting the host hijacking function of NSP12. [Abstract]

2026 Jul;16(7):4410-4425. PMID: 42453420
Acta Pharm Sin B

Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics. [Abstract]

2024 Sep;14(9):4028-4044. PMID: 39309487
Sci Transl Med

S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. [Abstract]

2023 Jan 18;15(679):eabq4064. PMID: 36327352
Acta Pharm Sin B

Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2. [Abstract]

2021 Sep;11(9):2850-2858. PMID: 33723501
J Extracell Vesicles

Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection. [Abstract]

2022 Jan;11(1):e12179. PMID: 34982509
Nucleic Acids Res

COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]

2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390
Biomaterials

3D-printed airway model as a platform for SARS-CoV-2 infection and antiviral drug testing. [Abstract]

2024 Jun 25:311:122689. PMID: 38944967
Biomaterials

Generation of human tonsil epithelial organoids as an ex vivo model for SARS-CoV-2 infection. [Abstract]

2022 Apr:283:121460. PMID: 35286852
Cell Discov

Surface translocation of ACE2 and TMPRSS2 upon TLR4/7/8 activation is required for SARS-CoV-2 infection in circulating monocytes. [Abstract]

2022 Sep 9;8(1):89. PMID: 36085197
Redox Biol

SARS-CoV2 infection impairs the metabolism and redox function of cellular glutathione. [Abstract]

2021 Sep;45:102041. PMID: 34146958
J Control Release

Intranasal liposomal remdesivir induces SARS-CoV-2 clearance in K18-hACE2 mice and ensures survival. [Abstract]

2025 Jan 22:379:558-573. PMID: 39837387
EBioMedicine

Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids. [Abstract]

2022 Jul:81:104132. PMID: 35779493
MedComm (2020)

Disruption of Spike Priming in Virus Entry: Tetrandrine as a Pan-Coronavirus Inhibitor. [Abstract]

2025 Aug 31;6(9):e70353. PMID: 40900808
Cell Rep Med

Human liver-derived organoids recapitulate Oropouche virus infection and manifestation, enabling antiviral drug discovery. [Abstract]

2026 Mar 9:102646. PMID: 41806841
Int J Biol Sci

NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence via the induction of ASCT2. [Abstract]

2020 Oct 16;16(16):3100-3115. PMID: 33162818
Int J Biol Macromol

Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches. [Abstract]

2021 Jan 31;168:474-485. PMID: 33290767
Acta Pharmacol Sin

Carrimycin exhibited broad spectrum inhibitory activities against coronaviruses replication through down-regulating host factor TMEM41B. [Abstract]

2025 Jul;46(7):2006-2015. PMID: 40374896
Genes Dev

Targeting the m6A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication. [Abstract]

2021 Jul 1;35(13-14):1005-1019. PMID: 34168039
Mol Syst Biol

SARS-CoV-2 infection remodels the host protein thermal stability landscape. [Abstract]

2021 Feb;17(2):e10188. PMID: 33590968
Biomed Pharmacother

MG-101, a cysteine protease inhibitor identified through high-throughput screening, exhibits in vivo efficacy and synergy with remdesivir against SARS-CoV-2. [Abstract]

2026 Feb 2:196:119076. PMID: 41633253
Biomed Pharmacother

Drug repositioning: Identification of potent inhibitors of NS3 protease and NS5 RdRp for control of DENV infection. [Abstract]

2025 Apr 28:187:118104. PMID: 40300391
Emerg Microbes Infect

A novel transcription and replication-competent virus-like particles system modelling the Nipah virus life cycle. [Abstract]

2024 Jun 12:2368217. PMID: 38865205
Emerg Microbes Infect

Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. [Abstract]

2021 Dec;10(1):291-304. PMID: 33538646
Emerg Microbes Infect

The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. [Abstract]

2021 Dec;10(1):317-330. PMID: 33560940
Cell Chem Biol

Identifying enhancers of innate immune signaling as broad-spectrum antivirals active against emerging viruses. [Abstract]

2022 Jul 21;29(7):1113-1125.e6. PMID: 35728599
Cell Rep

An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo. [Abstract]

2024 Nov 5;43(11):114929. PMID: 39504242
Microbiol Res

Transcriptome dynamics of the BHK21 cell line in response to human coronavirus OC43 infection. [Abstract]

2024 May 15:285:127750. PMID: 38761489
Arch Toxicol

The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro. [Abstract]

2022 Aug;96(8):2341-2360. PMID: 35579693
Cell Rep

Contribution of autophagy machinery factors to HCV and SARS-CoV-2 replication organelle formation. [Abstract]

2021 Nov 23;37(8):110049. PMID: 34788596
Cell Rep

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. [Abstract]

2021 Apr 6;35(1):108959. PMID: 33811811
J Med Chem

Discovery, Optimization, and Evaluation of Non-Nucleoside SARS-CoV-2 NSP14 Inhibitors. [Abstract]

2025 Sep 25;68(18):19076-19106. PMID: 40910582
J Med Chem

Differential Bioactivation Profiles of Different GS-441524 Prodrugs in Cell and Mouse Models: ProTide Prodrugs with High Cell Permeability and Susceptibility to Cathepsin A Are More Efficient in Delivering Antiviral Active Metabolites to the Lung. [Abstract]

2024 May 9;67(9):7470-7486. PMID: 38690769
Int J Nanomedicine

Antiviral Lipid Nanocarrier Loaded with Remdesivir Effective Against SARS-CoV-2 in vitro Model. [Abstract]

2023 Mar 27:18:1561-1575. PMID: 37007987
J Cell Biol

SARS-CoV-2 NSP3/4 control formation of replication organelle and recruitment of RNA polymerase NSP12. [Abstract]

2025 Mar 3;224(3):e202306101. PMID: 39737877
Phytother Res

Ouratein D, a Biflavanone From Ouratea spectabilis, Alleviates Betacoronavirus Infection by Mitigating Inflammation, Lung Damage and Viral Replication. [Abstract]

2025 Mar 18. PMID: 40099709
Fundam Res

Tailoring combinational therapy with Monte Carlo method-based regression modeling. [Abstract]

2023 Apr 7;5(6):2975-2982. PMID: 41467005
Cell Biosci

Targeting stress induction of GRP78 by cardiac glycoside oleandrin dually suppresses cancer and COVID-19. [Abstract]

2024 Sep 6;14(1):115. PMID: 39238058
Eur J Med Chem

System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2. [Abstract]

2021 Nov 15:224:113683. PMID: 34273661
Bioeng Transl Med

IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development. [Abstract]

2020 Dec 1;6(1):e10196. PMID: 33532594
Biosensors (Basel)

Aptamer-Gated Mesoporous Silica Nanoparticles for N Protein Triggered Release of Remdesivir and Treatment of Novel Coronavirus (2019-nCoV). [Abstract]

2022 Nov 1;12(11):950. PMID: 36354459
Pharmaceutics

Multidrug Combinations against SARS-CoV-2 Using GS-441524 or Ivermectin with Molnupiravir and/or Nirmatrelvir in Reconstituted Human Nasal Airway Epithelia. [Abstract]

2024 Sep 27;16(10):1262. PMID: 39458594
Pharmaceutics

Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection. [Abstract]

2021 Oct 11;13(10):1656. PMID: 34683949
J Ethnopharmacol

Mechanistic insights into the dual anti-COVID-19 and anti-inflammatory actions of Zhengqi tablets. [Abstract]

2025 Aug 29:352:120249. PMID: 40619041
J Ethnopharmacol

Anticoronavirus activity of rhizome of Dryopteris crassirhizoma via multistage targeting of virus entry and viral proteases, Mpro and PLpro. [Abstract]

2024 Jun 25:333:118490. PMID: 38925321
J Mol Liq

Antiviral activities of 4H-chromen-4-one scaffold-containing flavonoids against SARS-CoV-2 using computational and in vitro approaches. [Abstract]

2022 May 1:353:118775. PMID: 35194277
Stem Cell Reports

Parallel use of human stem cell lung and heart models provide insights for SARS-CoV-2 treatment. [Abstract]

2023 Jun 13;18(6):1308-1324. PMID: 37315523
Commun Biol

Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. [Abstract]

2022 Feb 22;5(1):154. PMID: 35194144
Int J Mol Sci

Electrophysiological and Molecular Features of Remdesivir-Induced Cardiac Toxicity in Male and Female Guinea Pigs. [Abstract]

2026 Apr 21;27(8):3685. PMID: 42074328
PLoS Pathog

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. [Abstract]

2021 Sep 17;17(9):e1009929. PMID: 34534263
Int J Mol Sci

Pseudo-Dipeptide Bearing α,α-Difluoromethyl Ketone Moiety as Electrophilic Warhead with Activity against Coronaviruses. [Abstract]

2021 Jan 30;22(3):1398. PMID: 33573283
Front Cell Infect Microbiol

Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection. [Abstract]

2021 Jul 30:11:700502. PMID: 34395311
Biomolecules

In Vitro Anti-SARS-CoV-2 Activity of Selected Metal Compounds and Potential Molecular Basis for Their Actions Based on Computational Study. [Abstract]

2021 Dec 10;11(12):1858. PMID: 34944502
Front Pharmacol

Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of I K(M) or I K(DR) and in the Stimulation of I MEP. [Abstract]

2020 Jul 21;11:1091. PMID: 32792942
Pharmaceuticals (Basel)

COVID-19: A Brief Overview of the Discovery Clinical Trial. [Abstract]

2020 Apr 10;13(4):65. PMID: 32290348
Eur J Pharmacol

Iguratimod, a promising therapeutic agent for COVID-19 that attenuates excessive inflammation in mouse models. [Abstract]

2025 Mar 25:177537. PMID: 40147575
mBio

A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance. [Abstract]

2023 Aug 31;14(4):e0106023. PMID: 37338298
mBio

Strategy To Assess Zoonotic Potential Reveals Low Risk Posed by SARS-Related Coronaviruses from Bat and Pangolin. [Abstract]

2023 Apr 25;14(2):e0328522. PMID: 36786573
J Med Virol

Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection. [Abstract]

2025 Nov;97(11):e70713. PMID: 41263140
Molecules

Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity. [Abstract]

2022 Dec 12;27(24):8829. PMID: 36557962
J Med Virol

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. [Abstract]

2021 Mar;93(3):1403-1408. PMID: 32767684
Molecules

Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E). [Abstract]

2020 May 17;25(10):2343. PMID: 32429580
Antimicrob Agents Chemother

Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice. [Abstract]

2024 Sep 6:e0103924. PMID: 39240093
Antimicrob Agents Chemother

Inhibition of endocytic uptake of severe acute respiratory syndrome coronavirus 2 and endo-lysosomal acidification by diphenoxylate. [Abstract]

2024 May 14:e0034124. PMID: 38742905
Antimicrob Agents Chemother

Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals. [Abstract]

2023 Apr 18;67(4):e0170322. PMID: 36975844
Antimicrob Agents Chemother

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. [Abstract]

2020 Jun 23;64(7):e00819-20. PMID: 32366720
Biomed J

Perilla (Perilla frutescens) leaf extract inhibits SARS-CoV-2 via direct virus inactivation. [Abstract]

2021 Jun;44(3):293-303. PMID: 34119448
ACS Omega

Antiviral Activity of Dendritic Heparan Sulfate Mimetics against Respiratory Syncytial Virus and Herpes Simplex Virus‑1. [Abstract]

2026 Apr 30;11(18):26533-26543. PMID: 42146132
ACS Omega

Enzymatic Glucosylation Enhances the Solubility of Niclosamide but Abrogates Its Therapeutic Efficacy. [Abstract]

2026 Jan 26;11(5):8667-8677. PMID: 41696203
Int J Infect Dis

Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients. [Abstract]

2024 Jun 27:107134. PMID: 38944411
J Gen Virol

SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology. [Abstract]

2020 Sep;101(9):925-940. PMID: 32568027
Microorganisms

The New Generation h DHODH Inhibitor MEDS433 Hinders the In Vitro Replication of SARS-CoV-2 and Other Human Coronaviruses. [Abstract]

2021 Aug 14;9(8):1731. PMID: 34442810
Microorganisms

Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors. [Abstract]

2021 Mar 31;9(4):734. PMID: 33807492
Microorganisms

Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro. [Abstract]

2020 Nov 26;8(12):1872. PMID: 33256227
Comput Struct Biotechnol J

A DNA-based non-infectious replicon system to study SARS-CoV-2 RNA synthesis. [Abstract]

2022:20:5193-5202. PMID: 36059866
iScience

Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells. [Abstract]

2021 Dec 17;24(12):103412. PMID: 34786537
iScience

5-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2. [Abstract]

2021 Oct 22;24(10):103120. PMID: 34541466
Antiviral Res

Broad-spectrum antiviral screening reveals pyrimidine biosynthesis as a target for inhibiting measles virus replication. [Abstract]

2026 Jun:250:106413. PMID: 41967510
Antiviral Res

Genetic determinants of efficacy of antiviral drugs revealed by genome-wide CRISPR screens. [Abstract]

2025 Dec:244:106309. PMID: 41260510
Antiviral Res

Dexamethasone treatment does not alter mortality but reduces pulmonary pathology in Nipah virus-infected Syrian hamsters. [Abstract]

2025 Oct:242:106263. PMID: 40835030
Virol Sin

Development of a reporter HBoV1 strain for antiviral drug screening and life cycle studies. [Abstract]

2025 Mar 25:S1995-820X(25)00031-8. PMID: 40147635
Antiviral Res

Effectiveness of nucleoside analogs against Wetland virus infection. [Abstract]

2025 Apr:236:106114. PMID: 39954869
Antiviral Res

Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A. [Abstract]

2024 May:225:105856. PMID: 38447646
Antiviral Res

PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding. [Abstract]

2023 Sep:217:105700. PMID: 37562608
Virol Sin

Identification of a receptor tyrosine kinase inhibitor CP-724714 inhibits SADS-CoV related swine diarrhea coronaviruses infection in vitro. [Abstract]

2023 Oct;38(5):778-786. PMID: 37406816
Antiviral Res

Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors. [Abstract]

2023 Aug:216:105671. PMID: 37451629
Antiviral Res

Development of a novel minigenome and recombinant VSV expressing Seoul hantavirus glycoprotein-based assays to identify anti-hantavirus therapeutics. [Abstract]

2023 Jun:214:105619. PMID: 37142192
Antiviral Res

Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2. [Abstract]

2023 Jun:214:105606. PMID: 37076089
Antiviral Res

Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters. [Abstract]

2022 Aug:204:105365. PMID: 35732228
Antiviral Res

Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro. [Abstract]

2021 Jul:191:105089. PMID: 34010661
J Neural Transm (Vienna)

Remdesivir shifts circadian rhythmicity to eveningness; similar to the most prevalent chronotype in ADHD. [Abstract]

2021 Jul;128(7):1159-1168. PMID: 34273024
Antiviral Res

Advancing Marburg virus antiviral screening: Optimization of a novel T7 polymerase-independent minigenome system. [Abstract]

2021 Jan;185:104977. PMID: 33220335
Antiviral Res

Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. [Abstract]

2020 Dec;184:104955. PMID: 33091434
Antiviral Res

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. [Abstract]

2020 Jun;178:104786. PMID: 32251767
Sci Rep

Glycan-binding properties of SARS-CoV-2 spike proteins: interactions with aminoglycoside antibiotics. [Abstract]

2026 Mar 9. PMID: 41803230
Sci Rep

High-throughput in vitro screening and in silico analysis for Zika virus inhibitor identification. [Abstract]

2025 Nov 27. PMID: 41310171
Sci Rep

Harnessing prebiotic formamide chemistry: a novel platform for antiviral exploration. [Abstract]

2025 Aug 2;15(1):28197. PMID: 40750837
Sci Rep

In silico screening and experimental validation identify riboflavin as an RNA-targeted antiviral against SARS-CoV-2. [Abstract]

2025 Aug 22;15(1):30935. PMID: 40846756
Sci Rep

Construction and validation of a cell based reporter assay for identifying inhibitors of SARS coronavirus 2 RNA dependent RNA polymerase activity. [Abstract]

2025 May 26;15(1):18443. PMID: 40419748
Sci Rep

Inhibition of SARS-CoV-2 3CL protease by the anti-viral chimeric protein RetroMAD1. [Abstract]

2023 Nov 17;13(1):20178. PMID: 37978223
Sci Rep

Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models. [Abstract]

2021 Dec 6;11(1):23465. PMID: 34873274
Biomedicines

In Vitro Replication Inhibitory Activity of Xanthorrhizol against Severe Acute Respiratory Syndrome Coronavirus 2. [Abstract]

2021 Nov 19;9(11):1725. PMID: 34829954
Biomedicines

SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System. [Abstract]

2021 Aug 11;9(8):996. PMID: 34440200
Sci Rep

MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2. [Abstract]

2021 Mar 8;11(1):5376. PMID: 33686154
Sci Rep

The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication. [Abstract]

2021 Mar 8;11(1):5433. PMID: 33686143
Sci Rep

Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2. [Abstract]

2021 Jan 12;11(1):821. PMID: 33436985
Sci Rep

Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19. [Abstract]

2020 Oct 1;10(1):16200. PMID: 33004837
Microbiol Spectr

Host-directed antiviral strategy targeting prohibitins: Mel56 suppresses influenza A virus and severe acute respiratory syndrome coronavirus 2 via modulation of antioxidant pathways and mitochondrial function. [Abstract]

2026 May 15:e0309325. PMID: 42138434
ACS Infect Dis

Single-Molecule Assay Reveals Binding Dynamics of SARS-CoV-2 Polymerase Components and Provides a New Tool to Distinguish Polymerase Inhibitors. [Abstract]

2025 Jun 13;11(6):1518-1527. PMID: 40465830
Virol J

Mycophenolate mofetil exerts broad-spectrum antiviral activity against coronaviruses including SARS-CoV-2. [Abstract]

2025 Mar 4;22(1):56. PMID: 40038695
J Virol

An RNA replicon system to investigate promising inhibitors of feline coronavirus. [Abstract]

2024 Feb 20;98(2):e0121623. PMID: 38236006
Virol J

Bafilomycin A1 inhibits SARS-CoV-2 infection in a human lung xenograft mouse model. [Abstract]

2023 Jan 31;20(1):18. PMID: 36721152
J Virol

Comparison of Zaire and Bundibugyo Ebolavirus Polymerase Complexes and Susceptibility to Antivirals through a Newly Developed Bundibugyo Minigenome System. [Abstract]

2021 Sep 27;95(20):e0064321. PMID: 34379503
Mol Divers

CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy. [Abstract]

2021 Aug;25(3):1839-1854. PMID: 33389560
ACS Pharmacol Transl Sci

Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19. [Abstract]

2020 Oct 14;3(6):1278-1292. PMID: 33330842
J Antimicrob Chemother

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo. [Abstract]

2023 Apr 3;78(4):946-952. PMID: 36760083
Viruses

2025 Dec 27.
Viruses

4-Hydroxychalcone Inhibits Human Coronavirus HCoV-OC43 by Targeting EGFR/AKT/ERK1/2 Signaling Pathway. [Abstract]

2025 Jul 23;17(8):1028. PMID: 40872743
Viruses

2024 Apr 29, 16(5), 708.
J Neuroimmune Pharmacol

Differential Cytokine Responses of APOE3 and APOE4 Blood-brain Barrier Cell Types to SARS-CoV-2 Spike Proteins. [Abstract]

2024 May 21;19(1):22. PMID: 38771543
Viruses

Molecular Analyses of Clinical Isolates and Recombinant SARS-CoV-2 Carrying B.1 and B.1.617.2 Spike Mutations Suggest a Potential Role of Non-Spike Mutations in Infection Kinetics. [Abstract]

2022 Sep 12;14(9):2017. PMID: 36146823
Viruses

A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants. [Abstract]

2022 Jun 23;14(7):1369. PMID: 35891350
Viruses

Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19. [Abstract]

2022 Feb 8;14(2):353. PMID: 35215943
Viruses

Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. [Abstract]

2021 Apr 2;13(4):610. PMID: 33918368
Viruses

In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. [Abstract]

2021 Mar 26;13(4):558. PMID: 33810356
Viruses

Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture. [Abstract]

2021 Feb 9;13(2):271. PMID: 33572467
Viruses

IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro. [Abstract]

2020 Dec 5;12(12):1394. PMID: 33291455
Viruses

Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). [Abstract]

2020 Jun 10;12(6):628. PMID: 32532085
Pathogens

Antiviral Activity of Pyrazolopyrimidine and Triazolopyrimidine Derivatives Against SARS-CoV-2 In Vitro: Identifying PZP25 as a Promising Scaffold. [Abstract]

2026 Mar 18;15(3):324. PMID: 41901777
Anim Cells Syst

CD47-mediated purification of human ventricular cardiomyocytes derived from pluripotent stem cells. [Abstract]

2026 Apr 20;30(1):381-393. PMID: 42027966
IUBMB Life

Endoplasmic reticulum stress and NF-kB activation in SARS-CoV-2 infected cells and their response to antiviral therapy. [Abstract]

2022 Jan;74(1):93-100. PMID: 34390301
mSphere

Development of a New Reverse Genetics System for Ebola Virus. [Abstract]

2021 May 5;6(3):e00235-21. PMID: 33952663
Biosaf Health

Drupacine as a potent SARS-CoV-2 replication inhibitor in vitro. [Abstract]

2024 Sep 3;6(5):270-278. PMID: 40078736
J Appl Toxicol

The mechanism and effects of remdesivir-induced developmental toxicity in zebrafish: Blood flow dysfunction and behavioral alterations. [Abstract]

2022 Oct;42(10):1688-1700. PMID: 35560222
Clin Transl Sci

Exploration for the effect of renal function and renal replacement therapy on pharmacokinetics of remdesivir and GS-441524 in patients with COVID-19: A limited case series. [Abstract]

2022 Mar;15(3):732-740. PMID: 34761554
Clin Transl Sci

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. [Abstract]

2022 Feb;15(2):501-513. PMID: 34719115
J Chromatogr B Analyt Technol Biomed Life Sci

Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma. [Abstract]

2021 May 1:1171:122641. PMID: 33756448
Virus Res

Characterization of minigenome systems for Hantaan and Seoul hantaviruses. [Abstract]

2026 Jan:363:199678. PMID: 41419169
PLoS One

Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection. [Abstract]

2025 Feb 5;20(2):e0316952. PMID: 39908288
PLoS One

Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients. [Abstract]

2022 Nov 10;17(11):e0276751. PMID: 36355808
Chem Zvesti

RETRACTED ARTICLE: Discovery of (E)- N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drug. [Abstract]

2021;75(9):4669-4685. PMID: 34025012
New J Chem

2020 Oct 12.
J Hum Lact

Remdesivir and Human Milk: A Case Study. [Abstract]

2022 May;38(2):248-251. PMID: 35189734
bioRxiv

2026 Jun 13.
bioRxiv

2026 May 15.
bioRxiv

Recovery of proofreading-impaired SARS-CoV-2 reveals a mutator phenotype and an ExoN activity threshold for viability. [Abstract]

2026 May 12:2026.05.12.724615. PMID: 42182104
bioRxiv

2026 Mar 24.
SSRN

2026 Mar 7.
Michigan State University

2025.
bioRxiv

2025 Oct 8.
bioRxiv

2025 Oct 20.
SSRN

2025 Sep 19.
Patent

US20250268848A1.
Patent

US20250250647A1.
NAR Mol Med

Mechanism and spectrum of inhibition of viral polymerases by 2'-deoxy-2'-β-fluoro-4'-azidocytidine or azvudine. [Abstract]

2025 Aug 11;2(3):ugaf029. PMID: 40900943
bioRxiv

2025 Jun 23.
SSRN

2025 May 30.
Res Sq

2025 Apr 20.
Patent

US20250123269A1.
bioRxiv

2025 February 28.
Patent

US20250049841A1.
bioRxiv

Single-molecule assay reveals the impact of composition, RNA duplex, and inhibitors on the binding dynamics of SARS-CoV-2 polymerase complex. [Abstract]

2025 Jan 10:2025.01.10.632212. PMID: 39829757
Patent

US20240352022A1
Patent

US20240390328A1.
medRxiv

Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections. [Abstract]

2024 Jun 18:2024.06.14.24308523. PMID: 38946967
bioRxiv

2024 Mar 1.
Preprints

2024 Feb 19.
Preprints

2024 Jan 3.
SSRN

2024 Jan 26.
bioRxiv

2024 Jan 6.
bioRxiv

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. [Abstract]

2024 Feb 9:2023.11.20.567873. PMID: 38045308
Patent

US20230312571A1.
University of California

2023 Jun.
Patent

US20230123135A1.
Research Square Preprint

2023 Apr 5.
SSRN

2023 Mar 30.
Front Drug Discov

2023 Jan 5.
bioRxiv

2023 Mar 9.
bioRxiv

2023 Feb 24.
Utah State University

2023 Feb 1.
Ruprecht Karls University

2023.
Patent

US20220389050A1.
Patent

US20220380769A1.
Patent

US20220339132A1.
Patent

US20220339140A1.
Patent

US20220288080A1.
Preprints

2022, 2022070375.
Preprints

2022, 2022050381.
Curr Res Virol Sci

Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern. [Abstract]

2022;3:100019. PMID: 35072124
bioRxiv

January 03, 2022.
bioRxiv

January 10, 2022.
University of Texas

2021.
Eur Rev Med Pharmacol Sci

In vitro and clinical studies on the efficacy of α-cyclodextrin and hydroxytyrosol against SARS-CoV-2 infection. [Abstract]

2021 Dec;25(1 Suppl):81-89. PMID: 34890038
Patent

US20210379058A1.
bioRxiv

Sulforaphane exhibits in vitro and in vivo antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses. [Abstract]

2021 Mar 25:2021.03.25.437060. PMID: 33791708
Patent

US20210346411A1.
Research Square Preprint

2021 Aug.
Patent

US20210220377A1.
bioRxiv

Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524). [Abstract]

2021 Aug 10:2021.08.06.455494. PMID: 34401879
Phytomed Plus

The potential of BEN815 as an anti-inflammatory, antiviral and antioxidant agent for the treatment of COVID-19. [Abstract]

2021 Nov;1(4):100058. PMID: 35403084
Res Sq

Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters. [Abstract]

2020 Oct 7:rs.3.rs-86169. PMID: 33052331
Universidade de São Paulo

2020 Sep.
ChemRxiv

2020 Jun.
bioRxiv

2020 May.
F1000Res

2020 May.
bioRxiv

2020 May.
bioRxiv

2020 Apr.
bioRxiv

2020 Apr.
bioRxiv

2020 Mar.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (165.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6595 mL

8.2977 mL

16.5953 mL

5 mM

0.3319 mL

1.6595 mL

3.3191 mL

10 mM

0.1660 mL

0.8298 mL

1.6595 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.17 mg/mL (3.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.17 mg/mL (3.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (276 KB)
SDS (558 KB)
- English - EN (558 KB)
- Français - FR (558 KB)
- Deutsch - DE (558 KB)
- Norwegian - NO (558 KB)
- Español - ES (558 KB)
- Swedish - SV (558 KB)
- Italian - IT (558 KB)
- Korean - KR (558 KB)
- Portuguese - PT (558 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Agostini ML, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio. 2018 Mar 6;9(2). pii: e00221-18. [Content Brief]

[2]. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. [Content Brief]

[3]. Hu H, et al. Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity. J Med Chem. 2022 Sep 22;65(18):12044-12054. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6595 mL	8.2977 mL	16.5953 mL	41.4883 mL
	5 mM	0.3319 mL	1.6595 mL	3.3191 mL	8.2977 mL
	10 mM	0.1660 mL	0.8298 mL	1.6595 mL	4.1488 mL
	15 mM	0.1106 mL	0.5532 mL	1.1064 mL	2.7659 mL
	20 mM	0.0830 mL	0.4149 mL	0.8298 mL	2.0744 mL
	25 mM	0.0664 mL	0.3319 mL	0.6638 mL	1.6595 mL
	30 mM	0.0553 mL	0.2766 mL	0.5532 mL	1.3829 mL
	40 mM	0.0415 mL	0.2074 mL	0.4149 mL	1.0372 mL
	50 mM	0.0332 mL	0.1660 mL	0.3319 mL	0.8298 mL
	60 mM	0.0277 mL	0.1383 mL	0.2766 mL	0.6915 mL
	80 mM	0.0207 mL	0.1037 mL	0.2074 mL	0.5186 mL
	100 mM	0.0166 mL	0.0830 mL	0.1660 mL	0.4149 mL

Keywords

Remdesivir

226 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Remdesivir

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Classic FDA-Approved Drug Library

MedChemExpress（MCE）の使用を引用している文献 Remdesivir

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (226)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Remdesivir

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Classic FDA-Approved Drug Library

MedChemExpress（MCE）の使用を引用している文献 Remdesivir

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (226)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Remdesivir 関連分類

HY-104077 関連分類